Table 1.
Patient characteristics of all AML patients in the study.
| Demographics for GSKp219 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Raw numbers | |||||||||||||
| Treated |
Treated |
||||||||||||
| All cases | Lowest 2/3rd | Highest 3rd | P | Test used | All cases | Lowest 2/3rd | Highest 3rd | P | Test used | ||||
| Number | 511 | 341 | 170 | NA | Chi square | Number | 511 | 341 | 170 | NA | Chi square | ||
| Gender | M | 291 | 203 | 88 | 0.1153 | Gender | M | 56.9% | 59.5% | 51.8% | 0.1153 | ||
| F | 220 | 138 | 82 | F | 43.1% | 40.5% | 48.2% | ||||||
| Age | Min | 15.8 | 16.01 | 15.83 | t-Test | Age | Min | 15.8 | 16.01 | 15.83 | F test | ||
| Max | 87.23 | 87.23 | 86.8 | Max | 87.23 | 87.23 | 86.8 | ||||||
| Median | 65.7 | 65 | 65.21 | 0.76 | Median | 65.7 | 65 | 65.21 | 0.76 | ||||
| FAB | M0 | 29 | 20 | 9 | < 0.00001 | Chi square | FAB | MO | 5.7% | 5.9% | 5.3% | < 0.00001 | Chi square |
| M1 | 55 | 39 | 16 | M1 | 10.8% | 11.4% | 9.4% | ||||||
| M2 | 169 | 127 | 42 | M2 | 33.1% | 37.2% | 24.7% | ||||||
| M4 | 119 | 66 | 53 | M4 | 23.3% | 19.4% | 31.2% | ||||||
| M5 | 50 | 19 | 31 | M5 | 9.8% | 5.6% | 18.2% | ||||||
| M6 | 27 | 21 | 6 | M6 | 5.3% | 6.2% | 3.5% | ||||||
| M7 | 10 | 7 | 3 | M7 | 2.0% | 2.1% | 1.8% | ||||||
| RAEBT | 33 | 29 | 4 | RAEBT | 6.5% | 8.5% | 2.4% | ||||||
| Unknown | 19 | 13 | 6 | Unknown | 3.7% | 3.8% | 3.5% | ||||||
| WHO | Abnormal cytogenetics | 47 | 33 | 14 | 0.1 | Chi square | WHO | Abnormal cytogenetics | 9.2% | 9.7% | 8.2% | 0.1 | Chi square |
| Therapy related | 73 | 49 | 24 | Therapy related | 14.3% | 14.4% | 14.1% | ||||||
| Multilineage dysplasia | 110 | 83 | 27 | Multilineage dysplasia | 21.5% | 24.3% | 15.9% | ||||||
| Not in others | 281 | 176 | 105 | Not in others | 55.0% | 51.6% | 61.8% | ||||||
| Cytogenetics | Favorable | 34 | 26 | 8 | 0.36 | Chi square | Cytogenetics | Favorable | 6.7% | 7.6% | 4.7% | 0.36 | Chi square |
| Intermediate | 225 | 170 | 82 | Intermediate | 44.0% | 49.9% | 48.2% | ||||||
| Unfavorable | 252 | 145 | 80 | Unfavorable | 49.3% | 42.5% | 47.1% | ||||||
| FLT3 | ITD | 83 | 49 | 34 | 0.145 | Chi square | FLT3 | ITD | 16.7% | 9.9% | 6.9% | 0.145 | Chi square |
| D835 | 25 | 17 | 8 | 0.92 | D835 | 5.0% | 3.4% | 1.6% | 0.92 | ||||
| Both | 9 | Both | |||||||||||
| NPM1 | 4BP insert | 55 | 179 | 89 | 0.76 | Chi square | NPM1 | 4BP insert | 16.3% | 83.6% | 81.7% | 0.76 | Chi square |
| WT | 283 | 35 | 20 | WT | 83.7% | 16.4% | 18.3% | ||||||
| ND | 173 | 127 | 61 | ND | 33.9% | 37.2% | 35.9% | ||||||
| Zubrod PS | 3 or 4 | 17 | 11 | 6 | Chi square | Zubrod PS | 3 or 4 | 3.3% | 3.2% | 3.5% | Chi square | ||
| AHD | ≥ 2 mo | 204 | 143 | 61 | 0.23 | Chi square | AHD | ≥ 2 mo | 39.9% | 41.9% | 35.9% | 0.23 | Chi square |
| Infection | Yes | 101 | 62 | 39 | 0.35 | Chi square | Infection | Yes | 19.8% | 18.2% | 22.9% | 0.35 | Chi square |
| WBC | Median | 8.8 | 6.9 | 19.25 | 0.02 | F test | WBC | Median | 8.8 | 6.9 | 19.3 | 0.02 | F test |
| Absolute blast count | Median | 1.8 | 1.13 | 3.54 | 0.28 | F test | Absolute blast count | Median | 1.8 | 1.1 | 3.5 | 0.28 | F test |
| Platelet | Median | 56.0 | 55 | 57 | 0.08 | F test | Platelet | Median | 56.0 | 55.0 | 57.0 | 0.08 | F test |
| Hemoglobin | Median | 9.6 | 9.6 | 9.45 | 0.15 | F test | Hemoglobin | Median | 9.6 | 9.6 | 9.5 | 0.15 | F test |
| % marrow blasts | Median | 46.0 | 44 | 57 | 0.0002 | F test | % marrow blasts | Median | 46.0 | 44.0 | 57.0 | 0.0002 | F test |
| % blood blasts | Median | 19.0 | 18 | 20.5 | 0.3 | F test | % blood blasts | Median | 19.0 | 18.0 | 20.5 | 0.3 | F test |
| Response | CR | 231 | 153 | 78 | 0.17 | Chi square | Response | CR | 56.5% | 44.9% | 45.9% | 0.17 | Chi square |
| Resistant | 136 | 101 | 35 | Resistant | 33.3% | 36.7% | 26.1% | ||||||
| Fail | 42 | 21 | 21 | Fail | 10.3% | 7.6% | 15.7% | ||||||
| Relapse | Yes | 151 | 93 | 58 | 0.09 | Chi square | Relapse | Yes | 65.4% | 60.8% | 74.4% | 0.09 | Chi square |
| Alive | Yes | 103 | 76 | 27 | 0.14 | Chi square | Alive | Yes | 20.2% | 22.3% | 15.9% | 0.14 | Chi square |
| Overall survival | Median, weeks | 40.85 | 44.14 | 35.14 | Overall survival | Median, weeks | 40.85 | 49.1 | |||||
| Remission duration | Median, weeks | 51.6 | 50 | 34.5 | Remission duration | Median, weeks | 51.6 | 52 | |||||